MX2017014846A - Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol. - Google Patents
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol.Info
- Publication number
- MX2017014846A MX2017014846A MX2017014846A MX2017014846A MX2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridin
- cyclopentyl
- diol
- propane
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000004146 Propane-1,2-diol Substances 0.000 title 1
- 229960004063 propylene glycol Drugs 0.000 title 1
- KJKKMMMRWISKRF-FQEVSTJZSA-N (2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol Chemical compound CC1=C(OC[C@@H](O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 KJKKMMMRWISKRF-FQEVSTJZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a una forma cristalina del compuesto (S)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-iI)-[1,2,4 ] oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1 ,2-diol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015061153 | 2015-05-20 | ||
| PCT/EP2016/061200 WO2016184939A1 (en) | 2015-05-20 | 2016-05-19 | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014846A true MX2017014846A (es) | 2018-02-19 |
| MX373293B MX373293B (es) | 2020-04-23 |
Family
ID=56068887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014846A MX373293B (es) | 2015-05-20 | 2016-05-19 | Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10385043B2 (es) |
| EP (1) | EP3298008B1 (es) |
| JP (1) | JP6674967B2 (es) |
| KR (2) | KR102220848B1 (es) |
| CN (2) | CN114573574B (es) |
| AU (1) | AU2016263472B2 (es) |
| BR (1) | BR112017024785B1 (es) |
| CA (1) | CA2981130C (es) |
| CL (1) | CL2017002822A1 (es) |
| CY (1) | CY1122506T1 (es) |
| DK (1) | DK3298008T3 (es) |
| EA (1) | EA035133B1 (es) |
| ES (1) | ES2770348T3 (es) |
| HR (1) | HRP20200001T1 (es) |
| HU (1) | HUE047646T2 (es) |
| IL (1) | IL255718B (es) |
| LT (1) | LT3298008T (es) |
| MA (1) | MA42107B1 (es) |
| MX (1) | MX373293B (es) |
| MY (1) | MY192358A (es) |
| PH (1) | PH12017502097B1 (es) |
| PL (1) | PL3298008T3 (es) |
| PT (1) | PT3298008T (es) |
| RS (1) | RS59788B1 (es) |
| SG (1) | SG11201708794PA (es) |
| SI (1) | SI3298008T1 (es) |
| TW (1) | TWI711609B (es) |
| UA (1) | UA119818C2 (es) |
| WO (1) | WO2016184939A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12017502097B1 (en) | 2015-05-20 | 2023-05-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2021148314A1 (en) | 2020-01-20 | 2021-07-29 | Idorsia Pharmaceuticals Ltd | Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| AU2023339761A1 (en) | 2022-09-14 | 2025-03-20 | Viatris Asia Pacific Pte. Ltd. | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
| WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| CA2051494C (en) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
| DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
| EP1070080A4 (en) | 1998-03-09 | 2004-12-29 | Smithkline Beecham Corp | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS |
| DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| JP3790472B2 (ja) | 1999-08-19 | 2006-06-28 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用 |
| SI1379525T1 (sl) | 2001-02-21 | 2007-12-31 | Astrazeneca Ab | Heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnih glutamatnih receptorjev |
| DE60329073D1 (de) | 2002-01-18 | 2009-10-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| CA2472713C (en) | 2002-01-18 | 2011-07-19 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| WO2003105771A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP2006528980A (ja) | 2003-05-15 | 2006-12-28 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類 |
| WO2005014525A2 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
| CA2539438A1 (en) | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| EP1758579A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| EP1804793A4 (en) | 2004-10-22 | 2010-03-31 | Merck Sharp & Dohme | 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS |
| EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| PL1863787T3 (pl) | 2005-03-23 | 2011-10-31 | Idorsia Pharmaceuticals Ltd | Uwodornione pochodne benzo[c]tiofenu jako immunomodulatory |
| CA2602478A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives |
| US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
| MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
| NZ563522A (en) | 2005-04-22 | 2010-01-29 | Daiichi Sankyo Co Ltd | Heterocyclic compound with immunosuppressive activity |
| KR20080000622A (ko) | 2005-04-26 | 2008-01-02 | 뉴로서치 에이/에스 | 신규한 옥사디아졸 유도체 및 이의 의학적 용도 |
| US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| WO2006135694A2 (en) | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
| EP1896446A1 (en) | 2005-06-24 | 2008-03-12 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| JP2008546836A (ja) | 2005-06-28 | 2008-12-25 | アストラゼネカ アクチボラグ | 新規な用途 |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| EP1979345B1 (en) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| WO2007098474A1 (en) | 2006-02-21 | 2007-08-30 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists |
| MX2008013990A (es) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
| AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
| CN101511827B (zh) * | 2006-09-07 | 2012-02-01 | 埃科特莱茵药品有限公司 | 作为免疫调制剂的吡啶-4-基衍生物 |
| CA2661315C (en) | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
| CN101522645B (zh) | 2006-09-21 | 2013-01-09 | 埃科特莱茵药品有限公司 | 苯衍生物及其免疫调节剂的用途 |
| JP2010504932A (ja) | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | 抗炎症および免疫抑制特性を有するオキサジアゾール誘導体 |
| JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
| SI2125797T1 (sl) | 2007-03-16 | 2014-03-31 | Actelion Pharmaceuticals Ltd. | Derivati amino-piridina kot agonisti receptorja s1p1/edg1 |
| WO2008151042A1 (en) | 2007-06-01 | 2008-12-11 | American International Group, Inc. | Method and system for projecting catastrophe exposure |
| BRPI0815190A2 (pt) | 2007-08-17 | 2015-03-31 | Actelion Pharmaceuticals Ltd | Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo |
| ES2547877T3 (es) | 2007-10-04 | 2015-10-09 | Merck Serono S.A. | Compuestos diaril-oxadiazol |
| BRPI0818457A2 (pt) | 2007-10-04 | 2015-04-14 | Merck Serono Sa | Derivados de oxadiazol |
| NZ585775A (en) | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| CA2703987A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
| RU2010128006A (ru) | 2007-12-10 | 2012-01-20 | Актелион Фармасьютиклз Лтд (Ch) | Производные тиофена в качестве агонистов sipi/edgi |
| EP2262799B1 (en) | 2008-03-06 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
| US20110046170A1 (en) | 2008-03-06 | 2011-02-24 | Martin Bolli | Novel pyrimidine-pyridine derivatives |
| NZ588438A (en) | 2008-03-07 | 2012-05-25 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl oxadiazole derivatives as immunomodulating agents |
| AU2009220893A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| CL2009000628A1 (es) * | 2008-03-17 | 2010-04-09 | Bial Portela & Companhia S A | Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros. |
| DK2291080T3 (en) | 2008-05-14 | 2015-12-07 | Scripps Research Inst | Novel modulator of sphingosinphosphatreceptorer |
| WO2010148649A1 (en) | 2009-06-26 | 2010-12-29 | Glaxo Group Limited | 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists |
| EP2454255B1 (en) * | 2009-07-16 | 2013-11-06 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
| ES2544086T3 (es) | 2011-01-19 | 2015-08-27 | Actelion Pharmaceuticals Ltd. | Derivados de 2-metoxi-piridin-4-ilo |
| WO2012112841A2 (en) * | 2011-02-18 | 2012-08-23 | Abbott Laboratories | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation |
| MX2014014138A (es) | 2012-05-22 | 2015-02-24 | Actelion Pharmaceuticals Ltd | Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico. |
| MA38482B1 (fr) | 2013-03-15 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine |
| PH12017502097B1 (en) * | 2015-05-20 | 2023-05-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
-
2016
- 2016-05-19 PH PH1/2017/502097A patent/PH12017502097B1/en unknown
- 2016-05-19 WO PCT/EP2016/061200 patent/WO2016184939A1/en not_active Ceased
- 2016-05-19 MY MYPI2017704351A patent/MY192358A/en unknown
- 2016-05-19 TW TW105115600A patent/TWI711609B/zh active
- 2016-05-19 HU HUE16724387A patent/HUE047646T2/hu unknown
- 2016-05-19 BR BR112017024785-2A patent/BR112017024785B1/pt active IP Right Grant
- 2016-05-19 CA CA2981130A patent/CA2981130C/en active Active
- 2016-05-19 ES ES16724387T patent/ES2770348T3/es active Active
- 2016-05-19 UA UAA201712367A patent/UA119818C2/uk unknown
- 2016-05-19 AU AU2016263472A patent/AU2016263472B2/en active Active
- 2016-05-19 LT LTEP16724387.2T patent/LT3298008T/lt unknown
- 2016-05-19 SG SG11201708794PA patent/SG11201708794PA/en unknown
- 2016-05-19 JP JP2017560155A patent/JP6674967B2/ja active Active
- 2016-05-19 SI SI201630640T patent/SI3298008T1/sl unknown
- 2016-05-19 PT PT167243872T patent/PT3298008T/pt unknown
- 2016-05-19 CN CN202210198351.2A patent/CN114573574B/zh active Active
- 2016-05-19 CN CN201680029127.3A patent/CN107667104B/zh active Active
- 2016-05-19 MA MA42107A patent/MA42107B1/fr unknown
- 2016-05-19 DK DK16724387.2T patent/DK3298008T3/da active
- 2016-05-19 EP EP16724387.2A patent/EP3298008B1/en active Active
- 2016-05-19 PL PL16724387T patent/PL3298008T3/pl unknown
- 2016-05-19 RS RS20200051A patent/RS59788B1/sr unknown
- 2016-05-19 MX MX2017014846A patent/MX373293B/es active IP Right Grant
- 2016-05-19 KR KR1020177036594A patent/KR102220848B1/ko active Active
- 2016-05-19 KR KR1020207011402A patent/KR20200044155A/ko not_active Withdrawn
- 2016-05-19 US US15/575,332 patent/US10385043B2/en active Active
- 2016-05-19 EA EA201792543A patent/EA035133B1/ru not_active IP Right Cessation
- 2016-05-19 HR HRP20200001TT patent/HRP20200001T1/hr unknown
-
2017
- 2017-11-08 CL CL2017002822A patent/CL2017002822A1/es unknown
- 2017-11-16 IL IL255718A patent/IL255718B/en active IP Right Grant
-
2019
- 2019-07-03 US US16/503,245 patent/US10836754B2/en active Active
-
2020
- 2020-01-23 CY CY20201100061T patent/CY1122506T1/el unknown
- 2020-10-14 US US17/070,876 patent/US11390615B2/en active Active
-
2022
- 2022-07-01 US US17/810,545 patent/US11834443B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501842A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
| PH12016501633B1 (en) | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| MX387401B (es) | Producción de 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida que contienen 2-alquil-4,4-dimetil-1,3-dioxanos. | |
| MX2019004569A (es) | Metodo para producir 3-alquilsulfanil-2-cloro-n-(1-alquil-1h-tetra zol-5-il)-4-trifluorometilbenzamidas. | |
| UA120058C2 (uk) | Пестицидні композиції | |
| PH12016501517A1 (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
| MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. | |
| MX369501B (es) | Proceso para la preparación de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
| TW201613871A (en) | Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| WO2015001572A3 (en) | Process for the preparation of intermediate of dolutegravir | |
| EP4549538A3 (en) | Improvement in or relating to organic compounds | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
| MX2017012661A (es) | Procesos para preparar cloruro de 2-tiofenocarbonilo. | |
| MX2021004996A (es) | Preparacion de 4-metiltetrahidropiranos 2-sustituidos a partir de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos como materiales de partida. | |
| ZA201708645B (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | |
| TN2017000065A1 (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
| IL250469B (en) | Process for the production of 1-isopropyl-3-{5-[1-(3-methoxypropyl)piperidine-4-yl]-[4,3,1]oxadiazol-2-yl}-1h-indazole oxalate | |
| IN2013CH05359A (es) | ||
| TW201613870A (en) | Crystalline anti-trichophyton agents and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |